First, CRISPR‐/Cas9‐mediated genome editing was used to disrupt the CDKL5 gene in U2OS osteosarcoma cells modified with the Flp‐InTM T‐RExTM system. The gene discussed is CDKL5; the disease is osteosarcoma.